Published in final edited form as:

Bioorg Med Chem. 2016 October 1; 24(19): 4544–4554. doi:10.1016/j.bmc.2016.07.057.

2-Oxoamide inhibitors of cytosolic group IVA phospholipase A₂ with reduced lipophilicity

Georgia Antonopoulou^{a,d}, Victoria Magrioti^a, Maroula G. Kokotou^a, Aikaterini Nikolaou^a, Efrosini Barbayianni^a, Varnavas D. Mouchlis^{b,c}, Edward A. Dennis^{b,c,*}, and George Kokotos^{a,*}

^aDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Athens 15771, Greece

^bDepartment of Chemistry and Biochemistry, School of Medicine, MC 0601, University of California, San Diego, La Jolla, CA 92093-0601, USA

^cDepartment of Pharmacology, School of Medicine, MC 0601, University of California, San Diego, La Jolla, CA 92093-0601, USA

^dInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece

Abstract

Cytosolic GIVA phospholipase A₂ (GIVA cPLA₂) initiates the eicosanoid pathway of inflammation and thus inhibitors of this enzyme constitute novel potential agents for the treatment of inflammatory diseases. Traditionally, GIVA cPLA₂ inhibitors have suffered systemically from high lipophilicity. We have developed a variety of long chain 2-oxoamides as inhibitors of GIVA PLA₂. Among them, AX048 was found to produce a potent analgesic effect. We have now reduced the lipophilicity of AX048 by replacing the long aliphatic chain with a chain containing an ether linked aromatic ring with in vitro inhibitory activities similar to AX048.

Graphical abstract

Keywords

GIVA cPLA₂; Inhibitors; Lipophilicity; 2-Oxoamides; Phospholipase A₂

*Corresponding authors. Tel.: +1 858 534 3055; fax: +1 858 534 7390 (E.A.D.); tel.: +30 210 727 4462; fax: +30 210 727 4761 (G.K.). edennis@ucsd.edu (E.A. Dennis), gkokotos@chem.uoa.gr (G. Kokotos).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Cytosolic Group IVA phospholipase A₂ (GIVA cPLA₂) is an enzyme which plays a central role in inflammatory diseases.^{1, 2} It catalyzes the hydrolysis of the ester bond at the *sn*-2 position of glycerophospholipids releasing free fatty acids, including arachidonic acid, and lysophospholipids. Arachidonic acid initiates the cascade of bioactive eicosanoids, while lysophospholipids may be converted to other bioactive lipids such as platelet activating factor (PAF) or lyso-phosphatidic acid (LPA). Therefore, inhibitors of PLA₂ may regulate the production of a large number of inflammatory mediators and their discovery has attracted widespread interest in finding new medicinal agents for the treatment of inflammatory diseases.

A great variety of synthetic GIVA cPLA₂ inhibitors have been reported in the literature and they have been summarized in recent review articles.^{2–4} The first inhibitor of GIVA cPLA₂ reported was the arachidonoyl trifluoromethyl ketone (**1**, Fig 1).⁵ Wyeth has reported a series of indole-based inhibitors.^{6–10}

Among them, ecopladib⁷ (**2**, Fig 1) showed oral efficacy in inflammation models and advanced to phase I clinical trials, while giripladib (**3**, Fig 1) showed oral efficacy in vivo and was advanced into a phase II clinical trial for osteoarthritis. However, the trials were terminated because of standard gastrointestinal issues. Another important class of inhibitors, pyrrolidine-based compounds, was developed by Shionogi. Pyrrophenone (**4**, Fig 1) is a potent inhibitor, which strongly inhibited arachidonic acid release, prostaglandin E₂, as well as thromboxane B₂ and leukotriene B₄ formation in human whole blood.^{11, 12} The structurally related inhibitor, pyrroxyphene¹³ (**5**, Fig 1) displayed anti-arthritic and anti-bone destructive action in a murine arthritis model.¹⁴ A great number of 1,3-disubstituted propan-2-ones have been synthesized and tested, for example compound **6**.^{15–22} We have developed various long chain 2-oxoamides as inhibitors of GIVA PLA₂.^{23–27} One of them, namely AX048 (**7**, Fig 1),²⁸ was found to be systemically bioavailable producing a potent analgesic effect. In vivo, intrathecal (30 µg) and systemic (0.2–3 mg/kg i.p.) administration of AX048 blocked carrageenan hyperalgesia and after systemic delivery in a model of spinally mediated hyperalgesia induced by substance P.

Usually, GIVA cPLA₂ inhibitors suffer from high lipophilicity, which has as a consequence poor aqueous solubility and poor bioavailability. In the past, efforts to lower the lipophilicity of GIVA cPLA₂ inhibitors have been accomplished.^{22, 29–31} As an example, Lehr and coworkers developed 1,3-disubstituted propan-2-ones with reduced lipophilicity.²² The aim of the present work is to develop 2-oxoamides with reduced lipophilicity focusing on the inhibitor AX048 which demonstrates analgesic effect.²⁸ In an effort to identify more “drug-like” inhibitors, several new 2-oxoamides were designed and synthesized and their in vitro activities are presented here.

2. Results and discussion

2.1. Design of inhibitors with reduced lipophilicity

The mechanistic details of GIVA cPLA₂ abstraction of its phospholipid substrate from the lipid-water interface at the membrane surface have recently been described.^{32, 33} Synthetic lipophilic inhibitors of this enzyme are likely to partition into membranes prior to interacting with the enzyme and good inhibitors have all possessed substantial lipophilicity. When the lipophilicity of an inhibitor decreases, the inhibitory potency may decrease, but bioavailability may increase.

Our goal in this study was to design inhibitors which retained the potency of AX48, but with reduced lipophilicity.

The lipophilicity of the inhibitors is measured by the ClogP value. In Figure 1, the ClogP values of several common GIVA cPLA₂ inhibitors, calculated by ChemOffice Ultra 11.00, are presented. It is quite clear that these inhibitors present a common drawback: high lipophilicity. The ClogP values for these inhibitors range from 6.55 to 10.75.

Inhibitors with such high values are not expected to present favorable ADME properties according to Lipinski's rule of five.³⁴ The main lipophilic part of the oxoamide inhibitor AX048 is the long aliphatic chain. To decrease the lipophilicity, we envisaged the replacement of it by chains incorporating an aromatic ring along with one or two ether oxygens. These ether oxygens can be placed either near or at remote distance from the activated carbonyl, which interacts with the active site serine. Another option is the introduction of polar functionalities such as a sulfonamide or carboxylic group, at the end of the hydrophobic chain which may reduce the lipophilicity.

The compounds shown in Figure 2 were designed specifically to reduce lipophilicity without compromising inhibitory potency.

2.2. Synthesis of inhibitors

For the synthesis of the designed 2-oxoamides, a variety of 2-hydroxy acids were synthesized as shown in Schemes 1 and 2. First, the known esters **8**³⁵ and **9**³⁶, and esters **12** and **14**, synthesized as depicted in Scheme 1, were reduced to alcohols **15a–d**. Amino alcohol **18**, protected by the tosyl group, was prepared by the reduction of acid **16** using the mixed anhydride/NaBH₄ method³⁷ (Scheme 1). Alcohols **15a–d** and **18** were oxidized to aldehydes and subsequently converted to cyanohydrins **19a–e** (Scheme 2). 2-Hydroxy acids **21a–e** were obtained by conversion to hydroxyamides and hydrolysis under basic conditions.

Ethyl γ -amino butyrate (**22**) and ethyl 5-aminopentanoate (**23**) were coupled with 2-hydroxy acids **21a–e** and the products either oxidized to 2-oxoamides **25a–c** containing an ester group, or first hydrolyzed and subsequently oxidized to 2-oxoamides **27a–d** containing a free carboxyl group (Scheme 3). 2-Oxoamide derivative **28**, containing a terminal free carboxyl group, was obtained by oxidative conversion of the phenyl group of compound **24e**

to carboxyl using $\text{NaIO}_4\text{-RuCl}_3$.^{38, 39} At the same time, the hydroxyamide functionality was also oxidized to an oxoamide (Scheme 3).

Compound **21d** was also coupled with *tert*-butyl 4-aminobutanoate (**30**). Oxidation of compound **31**, followed by treatment with trifluoroacetic acid afforded the target compound **33** (Scheme 4).

2.3. In vitro inhibition of GIVA cPLA₂, GVIA iPLA₂ and GV sPLA₂

All synthesized inhibitors were tested for inhibition of human GIVA cPLA₂, GVIA iPLA₂ and GV sPLA₂ using previously described mixed micelle-based assays.^{24–26} The inhibition results are presented in Table 1, either as percent inhibition or as $X_I(50)$ values. At first, the percent of inhibition for each PLA₂ enzyme at 0.091 mole fraction of each inhibitor was determined. Then, the $X_I(50)$ values were measured for compounds that displayed greater than 85% inhibition. The $X_I(50)$ is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%. The ClogP values of all synthesized inhibitors are also summarized in Table 1.

Initially, the long aliphatic chain of AX048 was replaced by chains containing an aromatic group along with an ether group. Analog **25b** exhibited very weak inhibitory activity on GIVA cPLA₂, but considerable activity on GVIA iPLA₂. However, analog **25a** inhibited both the intracellular enzymes GIVA cPLA₂ and GVIA iPLA₂ with $X_I(50)$ values of 0.020 and 0.013, respectively. In the case of 2-oxoamides containing an ester group, the position of the O atom influences the activity toward GVIA cPLA₂. When the oxygen is at the 6-position from the activated carbonyl group, inhibitor **25b** only weakly inhibits cPLA₂, while when it is on the other side of the aromatic group with a greater distance from the activated carbonyl, good inhibition is observed. The 2-oxoamides **27b** and **27a**, that contain a free carboxyl group, selectively inhibited GIVA cPLA₂ without affecting GVIA iPLA₂ activity. This is in agreement with our previous observations that 2-oxoamides containing a free carboxyl group selectively inhibit GIVA cPLA₂.^{25, 26, 40} The inhibitor containing the O atom nearer to the activated carbonyl presented less inhibitory potency than the one containing the O atom on the other side of the ring. Inhibitor **25a** not only possesses lower lipophilicity (ClogP 6.30) than that of AX048 (ClogP 7.61), but also exhibits the same inhibition of both GIVA cPLA₂ and GVIA iPLA₂ as AX048. In addition, the corresponding analog **27a** presented even better potency toward GIVA cPLA₂ ($X_I(50)$ values of 0.016) with a significantly lower lipophilicity (ClogP 5.32).

Compound **32**, containing two ether oxygens, did not present any significant inhibition of GIVA cPLA₂. However, increasing the distance between the oxoamide functionality and the free carboxyl by one carbon atom led to increase of the inhibitory potency on GIVA cPLA₂. Compound **27d** presents a $X_I(50)$ value of 0.013 for GIVA cPLA₂ and at the same time reduced lipophilicity (ClogP 4.82). Thus, compounds **27a** and **27d** clearly presented higher inhibitory potency on GIVA cPLA₂ in comparison to AX048 and its corresponding acid AX006²⁸ and considerably lower lipophilicity. In addition, both of them are more potent inhibitors of GIVA cPLA₂ than the widely known and commercially available inhibitor AATFMK ($X_I(50)$ value of 0.036).²¹

In another approach to reduce the lipophilicity, a sulfonamide group was introduced at the end of the long chain. Both the ethyl ester **25c** and the free acid **27c** presented lower lipophilicity (ClogP 5.69 and 4.71, respectively) than AX048. However, the *in vitro* activities were dramatically decreased. Only **25c** presented a weak inhibition of GIVA cPLA₂. Additionally, a carboxylic acid group was introduced at the end of the long chain, but this substitution resulted in a sizable reduction in the lipophilicity (ClogP 4.61). Unfortunately, this compound was inactive toward both GIVA cPLA₂ and GVIA iPLA₂. Thus, although the introduction of the sulfonamide or the carboxyl functionalities led to compounds with reduced lipophilicities (**25c**, **27c**, **28**), these compounds displayed a dramatic loss in the inhibitory activity.

3. Conclusion

Lipophilicity is a very important parameter in the case of GIVA cPLA₂ inhibitors because this enzyme exhibits its catalytic action at the lipid-water interface. Thus, a potential PLA₂ inhibitor has to possess substantial lipophilicity, which usually leads to unfavorable ADME properties. Efforts to reduce the lipophilicity are usually accompanied by reduced inhibitory activity. We achieved a reduction in the lipophilicity of the *in vivo* active 2-oxoamide inhibitor AX048 by replacing the long aliphatic chain with a chain containing an aromatic ring along with one or two ether oxygens. These new derivatives (**25a**, **27a** and **27d**) possess *in vitro* inhibitory activities against GIVA cPLA₂ and GVIA iPLA₂ similar to AX048. Thus, we achieved a reduction in the lipophilicity without compromising inhibitory potency.

4. Experimental section

4.1. General

Melting points were determined on a Buchi 530 apparatus and are uncorrected. NMR spectra were recorded on a Varian Mercury spectrometer. ¹H and ¹³C NMR spectra were recorded at 200 MHz and 50 MHz respectively in CDCl₃ or as specified. Chemical shifts are given in ppm, and peak multiplicities are described as follows: s, singlet, d, doublet, t, triplet and m, multiplet. Electron spray ionization (ESI) mass spectra were recorded on a Finnigan, Surveyor MSQ Plus spectrometer. TLC plates (Silica Gel 60 F254) and Silica Gel 60 (70–230 or 230–400 mesh) for column chromatography were purchased from Merck. Spots were visualized with UV light and/or phosphomolybdic acid and/or ninhydrin, both in EtOH. Dichloromethane was dried by standard procedures and stored over molecular sieves. All other solvents and chemicals were reagent grade and used without further purification.

The synthesis of compounds **8**,³⁵ **9**³⁶ has been described previously.

4.2. Chemistry

4.2.1. (E)-Methyl 12-phenyldodec-11-enoate (11)—To a stirred solution of Br[−]P⁺Ph₃(CH₂)₉COOCH₃ (579 mg, 1.1 mmol) in dry THF (4 mL) under N₂ atmosphere, NaH (53 mg, 2.2 mmol) was added, followed by a solution of benzaldehyde (106 mg, 1.0 mmol) in dry THF (0.3 mL). The reaction mixture was stirred under N₂ atmosphere overnight at room temperature. The organic solvent was evaporated under reduced pressure, and H₂O (5 mL) was added dropwise. The product was extracted with Et₂O (3 × 5 mL), and

the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc 95:5 as eluent. Yield 76%; white oil; ¹H NMR (200 MHz, CDCl₃): δ 7.34–7.14 (m, 5H, Ph), 6.38 (d, 1H, PhCH=CH, *J* = 11.8 Hz), 5.70–5.57 (dt, 1H, PhCH=CH, *J*₁ = 11.8 Hz, *J*₂ = 7.0 Hz), 3.63 (s, 3H, OCH₃), 2.35–2.20 (m, 4H, CH₂CO, CH₂), 1.75–1.55 (m, 2H, CH₂), 1.40–1.35 (m, 2H, CH₂), 1.34–1.10 (m, 10H, 5 × CH₂); ¹³C NMR (50 MHz, CDCl₃): δ 174.2, 137.7, 133.1, 128.7, 128.0, 126.3, 125.8, 51.3, 34.0, 33.0, 29.9, 29.3, 29.2, 29.1, 29.0, 28.5, 24.9. Anal. Calcd for C₁₉H₂₈O₂: C, 79.12; H, 9.78. Found: C, 79.01; H, 9.92.

4.2.2. Methyl 12-phenyldodecanoate (12)—To a solution of **11** (288 mg, 1.0 mmol) in EtOH (5 mL) (through which N₂ had been passed for 5 min), 10% Pd/C catalyst (11 mg) was added. The reaction mixture was stirred under H₂ atmosphere overnight at room temperature. The catalyst was removed by filtration through a pad of Celite, and the organic solvent was evaporated under reduced pressure. The residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc as eluent. Yield 81%; oil; ¹H NMR (200 MHz, CDCl₃): δ 7.39–7.20 (m, 5H, Ph), 3.74 (s, 3H, OCH₃), 2.69 (t, 2H, PhCH₂, *J* = 7.2 Hz), 2.38 (t, 2H, CH₂CO, *J* = 7.4 Hz), 1.78–1.60 (m, 4H, 2 × CH₂), 1.42–1.15 (m, 14H, 7 × CH₂); ¹³C NMR (50 MHz, CDCl₃): δ 174.0, 142.7, 128.2, 128.1, 125.4, 51.2, 35.9, 34.0, 31.4, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 24.8. Anal. Calcd for C₁₉H₃₀O₂: C, 78.57; H, 10.41. Found: C, 78.22; H, 10.58.

4.2.3. Ethyl 4-(4-(hexyloxy)phenoxy)butanoate (14)—To a stirred solution of **13** (194 mg, 1.0 mmol) in acetone (8 mL), K₂CO₃ (414 mg, 3 mmol) and ethyl 4-bromobutyrate (0.2 mL, 1.5 mmol) were added and the reaction mixture was refluxed overnight. The organic solvent was evaporated under reduced pressure and the residue was treated with H₂O to remove potassium carbonate and extracted with CH₂Cl₂ (3 × 5 mL). The organic solvent was evaporated under reduced pressure and the residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc 8/2 as eluent. Yield 100%; colourless oil; ¹H NMR (200 MHz, CDCl₃): δ 6.90–6.70 (m, 4H, arom), 4.09 (q, 2H, OCH₂CH₃, *J* = 6.0 Hz), 3.90 (t, 2H, OCH₂, *J* = 6.0 Hz), 3.84 (t, 2H, OCH₂, *J* = 6.0 Hz), 3.42 (t, 2H, CH₂COO, *J* = 6.0 Hz), 2.60–2.30 (m, 4H, 2 × CH₂), 2.20–1.90 (m, 4H, 2 × CH₂), 1.71 (quintet, 2H, CH₂, *J* = 6.0 Hz), 1.22 (t, 3H, OCH₂CH₃, *J* = 6.0 Hz), 0.86 (t, 3H, CH₃, *J* = 6.0 Hz); ¹³C NMR (50 MHz, CDCl₃): δ 173.1, 153.2, 152.7, 115.1, 68.4, 67.1, 60.2, 32.3, 30.7, 29.2, 27.6, 25.6, 24.6, 14.1, 13.9. Anal. Calcd for C₁₈H₂₈O₄: C, 70.10; H, 9.15. Found: C, 69.98; H, 9.30.

4.2.4. General method for the reduction of esters to alcohols—To a stirred solution of the ester **8**, **9** or **12** (1.0 mmol) in dry Et₂O (10 mL), a solution of 1.0 M DIBALH in hexane (2.5 mL, 2.5 mmol) was added dropwise under N₂ atmosphere at room temperature. The mixture was stirred for 2 h after the addition was complete, and then H₂O (5 mL) was added dropwise. The entire mixture was stirred for 30 more min, and then filtered through a pad of Celite. The filtrate was evaporated under reduced pressure and the residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc as eluent.

4.2.4.1. 5-(4-(Hexyloxy)phenyl)pentan-1-ol (15a): Yield 72%; oil; ^1H NMR (200 MHz, CDCl_3): δ 7.29 (d, 2H, arom, $J = 8.8$ Hz), 7.03 (d, 2H, arom, $J = 8.8$ Hz), 4.15 (t, 2H, CH_2OPh , $J = 6.6$ Hz), 3.84 (t, 2H, CH_2OH , $J = 6.2$ Hz), 2.78 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 2.43 (bs, 1H, OH), 2.05–1.95 (m, 2H, CH_2), 1.88–1.45 (m, 12H, $6 \times \text{CH}_2$), 1.13 (t, 3H, CH_3 , $J = 6.6$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 157.2, 134.4, 129.1, 114.3, 68.0, 62.8, 34.9, 32.6, 31.6, 31.4, 29.3, 25.7, 25.3, 22.6, 14.0. Anal. Calcd for $\text{C}_{17}\text{H}_{28}\text{O}_2$: C, 77.22; H, 10.67. Found: C, 77.06; H, 10.85.

4.2.4.2. 4-(4-Octylphenoxy)butan-1-ol (15b): Yield 84%; white solid; mp 42–44 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.09 (d, 2H, arom, $J = 8.8$ Hz), 6.82 (d, 2H, arom, $J = 8.8$ Hz), 3.99 (t, 2H, CH_2OPh , $J = 5.8$ Hz), 3.73 (t, 2H, CH_2OH , $J = 5.8$ Hz), 2.55 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 2.38 (bs, 1H, OH), 1.98–1.20 (m, 16H, $8 \times \text{CH}_2$), 0.89 (t, 3H, CH_3 , $J = 6.2$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 156.8, 135.2, 129.2, 114.3, 67.7, 62.6, 35.0, 31.9, 31.7, 29.5, 29.4, 29.2, 25.9, 22.6, 14.1. Anal. Calcd for $\text{C}_{18}\text{H}_{30}\text{O}_2$: C, 77.65; H, 10.86. Found: C, 77.36; H, 10.98.

4.2.4.3. 12-Phenyldodecan-1-ol (15c): Yield 99%; white solid; mp 42–44 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.39–7.21 (m, 5H, Ph), 3.71 (t, 2H, CH_2OH , $J = 6.6$ Hz), 2.68 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 2.56 (bs, 1H, OH), 1.70–1.58 (m, 4H, $2 \times \text{CH}_2$), 1.45–1.24 (m, 16H, $8 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 142.9, 128.4, 128.2, 125.5, 63.1, 36.0, 32.8, 31.5, 29.6, 29.5, 29.4, 29.3, 25.7. Anal. Calcd for $\text{C}_{18}\text{H}_{30}\text{O}$: C, 82.38; H, 11.52. Found: C, 82.16; H, 11.79.

4.2.5. 4-(4-(Hexyloxy)phenoxy)butan-1-ol (15d)—To a stirred solution of the ester **14** (308 mg, 1.0 mmol) in dry THF (3.3 mL) a solution of 1.0 M LiAlH_4 in THF (1.1 mL, 1.1 mmol) was added dropwise under N_2 atmosphere and the mixture was refluxed for 4 h. After cooling to room temperature, HCl 1N (4.4 mL, 4.4 mmol) was added dropwise and the mixture was stirred for 1 h. The solvent was evaporated under reduced pressure and AcOEt and H_2O were added. The aqueous layer was separated and washed with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure and the residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc 6/4 as eluent. Yield 65%; white solid; mp 49–51 °C; ^1H NMR (200 MHz, CDCl_3): δ 6.80–6.60 (m, 4H, arom), 3.79 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.75 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.54 (t, 2H, CH_2OH , $J = 6.0$ Hz), 3.06 (bs, 1H, OH), 1.80–1.40 (m, 6H, $3 \times \text{CH}_2$), 1.40–1.10 (m, 6H, $3 \times \text{CH}_2$), 0.78 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 152.9, 152.6, 115.0, 68.2, 68.0, 61.8, 31.3, 29.0, 25.6, 25.4, 22.3, 20.6, 13.8. Anal. Calcd for $\text{C}_{16}\text{H}_{26}\text{O}_3$: C, 72.14; H, 9.84. Found: C, 72.02; H, 9.98.

4.2.6. 11-(4-Methylphenylsulfonamido)undecanoic acid (17)—To a solution of 11-amino-undecanoic acid (**16**) (201 mg, 1.0 mmol) in dry THF (1 mL), *N*-methylmorpholine was added (0.1 mL, 1.0 mmol) followed by a solution of tosyl chloride (191 mg, 1.0 mmol) in dry THF (1 mL), dropwise over 15 minutes. The reaction mixture was then stirred for 3 h. The organic solvent was evaporated under reduced pressure, H_2O (5 mL) was added, and the pH was adjusted to 2 with 6N HCl. The product was extracted with CHCl_3 (3×5 mL), and

the combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by column chromatography using $\text{CHCl}_3/\text{MeOH}$ 95:5 as eluent. Yield 30%; white solid; mp 78–80°C; ^1H NMR (200 MHz, CDCl_3): δ 9.60 (br s, 1H, COOH), 7.70 (d, 2H, arom, $J = 8.0$ Hz), 7.25 (d, 2H, arom, $J = 8.0$ Hz), 5.08 (br s, 1H, NH), 2.94–2.63 (m, 2H, NHCH_2), 2.37 (s, 3H, CH_3), 2.29 (t, 2H, CH_2COOH , $J = 7.4$ Hz), 1.62–0.95 (m, 16H, $8 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 179.3, 143.2, 136.8, 129.6, 127.0, 43.1, 33.9, 29.3, 29.2, 29.1, 29.0, 28.9, 26.4, 24.6, 21.4. Anal. Calcd for $\text{C}_{18}\text{H}_{29}\text{NO}_4\text{S}$: C, 60.82; H, 8.22; N, 3.94. Found: C, 60.72; H, 8.39; N, 3.84.

4.2.7. *N*-(11-Hydroxyundecyl)-4-methylbenzenesulfonamide (18)—To a stirred solution of **17** (355 mg, 1.0 mmol) in dry THF (5 mL) at -10°C , NMM (0.11 mL, 1.0 mmol) was added, followed by ClCOOEt (0.096 mL, 1.0 mmol). After 10 min, NaBH_4 (0.11 g, 3.0 mmol) was added in one portion. MeOH (10 mL) was then added dropwise to the mixture over a period of 10 min at 0°C . The solution was stirred for an additional 10 min and the organic solvents were evaporated under reduced pressure. The residue was neutralized with 1M aqueous KHSO_4 and the product was extracted with EtOAc (3×10 mL). The organic phase was washed with 1M aqueous KHSO_4 (5 mL), H_2O (10 mL), 5% aqueous NaHCO_3 (5 mL), and H_2O (10 mL), dried over Na_2SO_4 , and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography using $\text{CHCl}_3/\text{MeOH}$ 95:5 as eluent. Yield 45%; white solid; mp 63–65°C; ^1H NMR (200 MHz, CDCl_3): δ 7.72 (d, 2H, arom, $J = 8.0$ Hz), 7.22 (d, 2H, arom, $J = 8.0$ Hz), 4.68 (t, 1H, NH, $J = 6.4$ Hz), 3.60 (t, 2H, CH_2OH , $J = 6.6$ Hz), 2.98–2.80 (m, 2H, NHCH_2), 2.61 (bs, 1H, OH), 2.40 (s, 3H, CH_3), 1.62–1.10 (m, 18H, $9 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 143.2, 137.8, 129.6, 127.0, 63.0, 43.1, 32.7, 29.5, 29.3, 29.0, 26.4, 25.6, 21.5. Anal. Calcd for $\text{C}_{18}\text{H}_{31}\text{NO}_3\text{S}$: C, 63.31; H, 9.15; N, 4.10. Found: C, 63.21; H, 9.22; N, 4.01.

4.2.8. General method for the synthesis of cyanohydrins 19a–e—To a solution of the alcohol **15a–d** or **18** (1.0 mmol) in a mixture of toluene (3 mL) and EtOAc (3 mL), a solution of NaBr (0.11 g, 1.1 mmol) in water (0.5 mL) was added followed by AcNH-TEMPO (2.2 mg, 0.01 mmol). To the resulting biphasic system, which was cooled at 0°C , an aqueous solution of 0.35 M NaOCl (3.1 mL, 1.1 mmol) containing NaHCO_3 (0.25 g, 3 mmol) was added dropwise under vigorous stirring, at 0°C over a period of 1 h. After the mixture had been stirred for a further 15 min at 0°C , EtOAc (10 mL) and H_2O (10 mL) were added. The aqueous layer was separated and washed with EtOAc (2×10 mL). The combined organic layers were washed consecutively with 5% aqueous citric acid (10 mL) containing KI (0.04 g), 10% aqueous $\text{Na}_2\text{S}_2\text{O}_3$ (10 mL), and brine and dried over Na_2SO_4 . The solvents were evaporated under reduced pressure and the residue was used without any further purification.

To a stirred solution of the aldehyde (1 mmol) in CH_2Cl_2 (1.25 mL), a solution of NaHSO_3 (156 mg, 1.5 mmol) in water (0.25 mL) was added and the mixture was vigorously stirred for 30 min at room temperature. The organic solvent was evaporated under reduced pressure, water was added and the mixture was cooled at 0°C . Then, a solution of KCN (98 mg, 1.5 mmol) in water (0.25 mL) was added dropwise over a period of 3.5 h and the mixture was left under stirring overnight at room temperature. The aqueous suspension was extracted

with CH_2Cl_2 (2×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The solvent was evaporated under reduced pressure and the residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc as eluent.

4.2.8.1 6-(4-(Hexyloxy)phenyl)-2-hydroxyhexanenitrile (19a): Yield 80%; oil; ^1H NMR (200 MHz, CDCl_3): δ 7.09 (d, 2H, arom, $J = 8.8$ Hz), 6.84 (d, 2H, arom, $J = 8.8$ Hz), 4.44 (t, 1H, CHOH , $J = 7.0$ Hz), 3.95 (t, 2H, CH_2OPh , $J = 6.6$ Hz), 2.85 (bs, 1H, OH), 2.59 (t, 2H, PhCH_2 , $J = 7.0$ Hz), 1.92–1.74 (m, 4H, $2 \times \text{CH}_2$), 1.71–1.43 (m, 6H, $3 \times \text{CH}_2$), 1.40–1.31 (m, 4H, $2 \times \text{CH}_2$), 0.92 (t, 3H, CH_3 , $J = 7.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 157.3, 133.8, 129.2, 119.9, 114.5, 68.1, 61.2, 35.0, 34.6, 31.6, 30.9, 29.2, 25.7, 24.1, 22.6, 14.0. Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{NO}_2$: C, 74.70; H, 9.40; N, 4.84. Found: C, 74.58; H, 9.56; N, 4.73.

4.2.8.2. 2-Hydroxy-5-(4-octylphenoxy)pentanenitrile (19b): Yield 96%; white solid; mp 50–52 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.11 (d, 2H, arom, $J = 8.4$ Hz), 6.83 (d, 2H, arom, $J = 8.4$ Hz), 4.61 (br s, 1H, CHOH), 4.12–3.95 (m, 2H, PhOCH_2), 3.46 (br s, 1H, OH), 2.55 (t, 2H, CH_2Ph , $J = 7.6$ Hz), 2.15–1.95 (m, 4H, $2 \times \text{CH}_2$), 1.65–1.50 (m, 2H, CH_2), 1.38–1.19 (m, 10H, $5 \times \text{CH}_2$), 0.90 (t, 3H, CH_3 , $J = 6.2$); ^{13}C NMR (50 MHz, CDCl_3): δ 156.2, 135.8, 129.3, 119.8, 114.3, 67.2, 61.0, 35.0, 32.6, 31.8, 31.7, 29.4, 29.2, 24.7, 22.7, 14.1. Anal. Calcd for $\text{C}_{19}\text{H}_{29}\text{NO}_2$: C, 75.21; H, 9.63; N, 4.62. Found: C, 75.11; H, 9.78; N, 4.54.

4.2.8.3. 2-Hydroxy-13-phenyltridecanenitrile (19c): Yield 90%; white solid; mp 36–38 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.40–7.21 (m, 5H, Ph), 4.52 (t, 1H, CHOH , $J = 7.0$ Hz), 2.89 (br s, 1H, OH), 2.68 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 1.96–1.85 (m, 2H, CH_2), 1.78–1.60 (m, 2H, CH_2), 1.60–1.45 (m, 2H, CH_2), 1.45–1.10 (m, 14H, $7 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 142.9, 128.4, 128.2, 125.5, 120.0, 61.3, 35.9, 35.1, 29.5, 29.4, 29.3, 29.2, 28.9, 24.5. Anal. Calcd for $\text{C}_{19}\text{H}_{29}\text{NO}$: C, 79.39; H, 10.17; N, 4.87. Found: C, 79.28; H, 10.28; N, 4.75.

4.2.8.4. 5-(4-(Hexyloxy)phenoxy)-2-hydroxypentanenitrile (19d): Yield 45%; colourless oil; ^1H NMR (200 MHz, CDCl_3): δ 6.90–6.70 (m, 4H, arom), 4.55 (t, 1H, CHOH , $J = 6.0$ Hz), 3.94 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.89 (t, 2H, OCH_2 , $J = 6.0$ Hz), 2.10–1.90 (m, 4H, $2 \times \text{CH}_2$), 1.74 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.60–1.20 (m, 6H, $3 \times \text{CH}_2$), 0.89 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 153.4, 152.3, 119.9, 115.4, 68.6, 67.7, 60.8, 32.3, 31.5, 29.2, 25.6, 24.6, 22.5, 14.0. Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_3$: C, 70.07; H, 8.65; N, 4.81. Found: C, 69.90; H, 8.85; N, 4.92.

4.2.8.5. N-(11-Cyano-11-hydroxyundecyl)-4-methylbenzenesulfonamide (19e): Yield 73%; white solid; mp 77–79 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.72 (d, 2H, arom, $J = 8.4$ Hz), 7.28 (d, 2H, arom, $J = 8.4$ Hz), 4.73 (t, 1H, NH, $J = 5.8$ Hz), 4.45 (t, 1H, CHOH , $J = 6.6$ Hz), 2.88 (q, 2H, NHCH_2 , $J = 6.6$ Hz), 2.40 (s, 3H, CH_3), 1.85–1.70 (m, 2H, CH_2), 1.68–1.05 (m, 16H, $8 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 143.4, 136.8, 129.7, 127.0, 120.2, 61.2, 43.1, 35.1, 29.4, 29.1, 29.0, 28.8, 28.7, 26.3, 24.4, 21.5. Anal. Calcd for $\text{C}_{19}\text{H}_{30}\text{N}_2\text{O}_3\text{S}$: C, 62.26; H, 8.25; N, 7.64. Found: C, 62.19; H, 8.34; N, 7.57.

4.2.9. General method for the synthesis of 2-hydroxy-amides 20a–e—A solution of 2-hydroxy-nitrile **19a–e** (1.0 mmol) in conc. HCl (2.5 mL) was stirred overnight at room

temperature. Then, water was added and the aqueous solution was extracted with CHCl_3 (3×15 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The organic solvent was evaporated under reduced pressure and the resulting 2-hydroxyamide was precipitated using Et_2O .

4.2.9.1. 6-(4-(Hexyloxy)phenyl)-2-hydroxyhexanamide (20a): Yield 80%; white solid; mp 131–133 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.07 (d, 2H, arom, $J = 8.4$ Hz), 6.82 (d, 2H, arom, $J = 8.4$ Hz), 6.32 (br s, 1H, NH), 5.52 (br s, 1H, NH), 4.18–4.05 (m, 1H, CHOH), 3.93 (t, 2H, CH_2OPh , $J = 6.6$ Hz), 2.57 (t, 2H, CH_2 , $J = 7.4$ Hz), 2.40 (bs, 1H, OH), 2.25–1.98 (m, 2H, CH_2), 1.93–1.10 (m, 12H, $6 \times \text{CH}_2$), 0.91 (t, 3H, CH_3 , $J = 6.6$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 174.2, 157.3, 133.9, 129.1, 114.6, 74.9, 68.0, 35.8, 35.0, 31.4, 30.8, 29.3, 25.6, 24.4, 22.6, 14.0. Anal. Calcd for $\text{C}_{18}\text{H}_{29}\text{NO}_3$: C, 70.32; H, 9.51; N, 4.56. Found: C, 70.26; H, 9.62; N, 4.47.

4.2.9.2. 2-Hydroxy-5-(4-octylphenoxy)pentanamide (20b): Yield 67%; white solid; mp 130–132 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.05 (d, 2H, arom, $J = 8.4$ Hz), 6.80 (d, 2H, arom, $J = 8.4$ Hz), 6.31 (br, 1H, NH), 5.63 (br, 1H, NH), 4.15–4.05 (m, 1H, CHOH), 3.97 (t, 2H, PhOCH_2 , $J = 5.8$ Hz), 2.52 (t, 2H, CH_2Ph , $J = 7.2$ Hz), 2.38 (bs, 1H, OH), 2.04–1.77 (m, 4H, $2 \times \text{CH}_2$), 1.78–1.65 (m, 1H, CHH), 1.60–1.45 (m, 3H, $1 \times \text{CH}_2$, CHH), 1.38–1.02 (m, 8H, $4 \times \text{CH}_2$), 0.89 (t, 3H, CH_3 , $J = 6.2$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 174.1, 156.4, 135.6, 129.2, 114.3, 75.0, 67.5, 35.8, 35.0, 32.0, 31.7, 31.4, 29.4, 29.3, 24.8, 22.0, 14.1. Anal. Calcd for $\text{C}_{19}\text{H}_{31}\text{NO}_3$: C, 70.99; H, 9.72; N, 4.36. Found: C, 70.87; H, 9.81; N, 4.28.

4.2.9.3. 2-Hydroxy-13-phenyltridecanamide (20c): Yield 73%; white solid; mp 117–119 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.27–7.17 (m, 5H, Ph), 6.33 (br s, 1H, NH), 5.52 (br s, 1H, NH), 4.20–4.02 (m, 1H, CHOH), 2.61 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 2.46 (br s, 1H, OH), 1.95–1.78 (m, 1H, CHH), 1.75–1.50 (m, 3H, CHH , CH_2), 1.48–1.02 (m, 16H, $8 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 174.1, 142.9, 128.4, 128.3, 125.5, 75.0, 36.0, 34.8, 31.4, 29.5, 29.4, 29.2, 29.1, 28.0. Anal. Calcd for $\text{C}_{19}\text{H}_{31}\text{NO}_2$: C, 74.71; H, 10.23; N, 4.59. Found: C, 74.63; H, 10.35; N, 4.48.

4.2.9.4. 5-(4-(Hexyloxy)phenoxy)-2-hydroxypentanamide (20d): Yield 65%; white solid; mp 146–148 °C; ^1H NMR (200 MHz, CDCl_3): δ 6.90–6.70 (m, 4H, arom), 6.58 (bs, 1H, NH), 5.48 (bs, 1H, NH), 4.30–4.10 (m, 1H, CHOH), 3.98 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.89 (t, 2H, OCH_2 , $J = 6.0$ Hz), 2.10–1.50 (m, 6H, $3 \times \text{CH}_2$), 1.50–1.20 (m, 6H, $3 \times \text{CH}_2$), 0.89 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 172.6, 153.2, 152.6, 115.3, 71.1, 68.6, 68.3, 31.4, 31.1, 29.1, 25.5, 25.0, 22.4, 13.8. Anal. Calcd for $\text{C}_{17}\text{H}_{27}\text{NO}_4$: C, 65.99; H, 8.80; N, 4.53. Found: C, 65.79; H, 8.99; N, 4.68.

4.2.9.5. 2-Hydroxy-12-(4-methylphenylsulfonamido)dodecanamide (20e): Yield 50%; white solid; mp 101–103 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.75 (d, 2H, arom, $J = 8.4$ Hz), 7.30 (d, 2H, arom, $J = 8.4$ Hz), 6.47 (m, 1H, NH), 5.81 (m, 1H, CONHH), 4.93 (m, 1H, SO_2NH), 4.32–4.05 (m, 1H, CHOH), 3.00–2.82 (m, 2H, NHCH_2), 2.49 (bs, 1H, OH), 2.43 (s, 3H, CH_3), 2.00–1.58 (m, 4H, $2 \times \text{CH}_2$), 1.55–1.05 (m, 14H, $7 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 174.2, 143.3, 136.7, 129.8, 127.0, 74.9, 43.1, 35.5, 29.5, 29.4, 29.2, 29.1,

28.0, 26.2, 24.3, 21.4. Anal. Calcd for $C_{19}H_{32}N_2O_4S$: C, 59.35; H, 8.39; N, 7.29;. Found: C, 59.27; H, 8.44; N, 7.21.

4.2.10. General method for the synthesis of 2-hydroxy-acids 21a–e—To a solution of 2-hydroxy-amide **20a–e** (1.0 mmol) in a mixture of EtOH/water (2:1, 10 mL), KOH (0.56 g, 10.0 mmol) was added and the reaction mixture was refluxed for 4 h. After cooling, EtOH was removed under reduced pressure, water was added and the aqueous solution was acidified with conc. H_2SO_4 until pH 1, followed by extraction with Et_2O (3×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The organic solvent was evaporated under reduced pressure and the residue was purified by recrystallization using $CHCl_3$ /petroleum ether (bp 40–60 °C).

4.2.10.1. 6-(4-(Hexyloxy)phenyl)-2-hydroxyhexanoic acid (21a): Yield 96%; white solid; mp 94–96 °C; 1H NMR (200 MHz, $CDCl_3$): δ 7.08 (d, 2H, arom, $J = 8.4$ Hz), 6.83 (d, 2H, arom, $J = 8.4$ Hz), 4.91 (bs, 1H, OH), 4.28 (dd, 1H, $CHOH$, $J_1 = 7.2$ Hz, $J_2 = 4.0$ Hz), 3.94 (t, 2H, CH_2O Ph, $J = 6.6$ Hz), 2.58 (t, 2H, $PhCH_2$, $J = 7.4$ Hz), 1.98–1.25 (m, 14H, $7 \times CH_2$), 0.92 (t, 3H, CH_3 , $J = 6.6$ Hz); ^{13}C NMR (50 MHz, $CDCl_3$): δ 179.8, 157.2, 134.2, 129.2, 114.4, 70.2, 68.1, 34.8, 34.0, 31.6, 31.3, 29.3, 25.7, 24.4, 22.6, 14.0. Anal. Calcd for $C_{18}H_{28}O_4$: C, 70.10; H, 9.15. Found: C, 70.01; H, 9.26.

4.2.10.2. 2-Hydroxy-5-(4-octylphenoxy)pentanoic acid (21b): Yield 92%; white solid; mp 102–104 °C; 1H NMR (200 MHz, $CDCl_3$): δ 7.10 (d, 2H, arom, $J = 8.0$ Hz), 6.82 (d, 2H, arom, $J = 8.4$ Hz), 4.48 (bs, 1H, OH), 4.36 (t, 1H, $CHOH$, $J = 6.6$ Hz), 4.00 (t, 2H, $PhOCH_2$, $J = 5.6$ Hz), 2.55 (t, 2H, CH_2Ph , $J = 7.4$ Hz), 2.14–1.86 (m, 4H, $2 \times CH_2$), 1.71–1.58 (m, 2H, CH_2), 1.38–1.15 (m, 10H, $5 \times CH_2$), 0.90 (t, 3H, CH_3 , $J = 7.0$ Hz); ^{13}C NMR (50 MHz, $CDCl_3$): δ 179.0, 156.6, 135.4, 129.2, 114.3, 70.0, 67.5, 35.0, 31.9, 31.7, 31.0, 29.5, 29.3, 24.9, 22.6, 14.1. Anal. Calcd for $C_{19}H_{30}O_4$: C, 70.77; H, 9.38. Found: C, 70.69; H, 9.45.

4.2.10.3. 2-Hydroxy-13-phenyltridecanoic acid (21c): Yield 98%; white solid; mp 62–64 °C; 1H NMR (200 MHz, $CDCl_3$): δ 7.93–7.21 (m, 5H, Ph), 5.80 (br s, 1H, OH), 4.35 (dd, 1H, $CHOH$, $J_1 = 7.2$ Hz, $J_2 = 4.0$ Hz), 2.68 (t, 2H, $PhCH_2$, $J = 7.4$ Hz), 1.95–1.79 (m, 2H, CH_2CHOH), 1.79–1.55 (m, 2H, CH_2), 1.50–1.15 (m, 16H, $8 \times CH_2$); ^{13}C NMR (50 MHz, $CDCl_3$): δ 179.7, 142.9, 128.4, 128.2, 125.5, 70.3, 36.0, 34.2, 31.5, 29.5, 29.4, 29.3, 29.2, 24.7. Anal. Calcd for $C_{19}H_{30}O_3$: C, 74.47; H, 9.87. Found: C, 74.39; H, 9.93.

4.2.10.4. 5-(4-(Hexyloxy)phenoxy)-2-hydroxypentanoic acid (21d): Yield 100%; white solid; mp 102–104 °C; 1H NMR (200 MHz, $CDCl_3$): δ 6.90–6.60 (m, 4H, arom), 4.92 (bs, 1H, OH), 4.30–4.00 (m, 1H, $CHOH$), 3.85 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.80 (t, 2H, OCH_2 , $J = 6.0$ Hz), 2.00–1.50 (m, 6H, $3 \times CH_2$), 1.50–1.10 (m, 6H, $3 \times CH_2$), 0.80 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, $CDCl_3$): δ 176.8, 153.1, 152.7, 115.2, 69.8, 68.5, 68.0, 31.4, 30.6, 29.1, 25.5, 24.8, 22.4, 13.8. Anal. Calcd for $C_{17}H_{26}O_5$: C, 65.78; H, 8.44. Found: C, 65.52; H, 8.66.

4.2.10.5. 2-Hydroxy-12-(4-methylphenylsulfonamido)dodecanoic acid (21e): Yield 82%; white solid; mp 83–85 °C; 1H NMR (200 MHz, $CDCl_3$): δ 7.70 (d, 2H, arom, $J = 8.0$ Hz), 7.25 (d, 2H, arom, $J = 8.0$ Hz), 5.15 (br s, 2H, NH, OH), 4.21 (dd, 1H, $CHOH$, $J_1 = 6.6$

Hz, $J_2 = 5.2$ Hz), 2.90–2.78 (m, 2H, NHCH_2), 2.37 (s, 3H, CH_3), 1.80–1.53 (m, 2H, CH_2), 1.44–1.35 (m, 4H, $2 \times \text{CH}_2$), 1.30–1.15 (m, 12H, $6 \times \text{CH}_2$); ^{13}C NMR (50 MHz, CDCl_3): δ 178.7, 143.3, 136.7, 129.6, 127.0, 70.2, 43.1, 34.0, 29.5, 29.3, 29.2, 29.0, 28.9, 26.3, 24.5, 21.4. Anal. Calcd for $\text{C}_{19}\text{H}_{31}\text{NO}_5\text{S}$: C, 59.19; H, 8.10; N, 3.63. Found: C, 59.06; H, 8.21; N, 3.48.

4.2.11 General method for the coupling of 2-hydroxy-acids—To a stirred solution of the 2-hydroxy-acid **21a-e** (1.0 mmol) and the amine (1.0 mmol) in CH_2Cl_2 (10 mL), Et_3N (0.3 mL, 2.2 mmol in case of hydrochloride salt of the amine or 0.15 mL, 1.1 mmol in case of free amine) and subsequently 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (WSCl) (0.21 g, 1.1 mmol) and 1-hydroxybenzotriazole (HOBt) (0.14 g, 1.0 mmol) were added at 0 °C. The reaction mixture was stirred for 1 h at 0 °C and overnight at room temperature. The solvent was evaporated under reduced pressure and EtOAc (20 mL) was added. The organic layer was washed consecutively with brine, 1 N HCl , brine, 5% NaHCO_3 , and brine, dried over Na_2SO_4 and evaporated under reduced pressure. The residue was purified by column chromatography using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1 as eluent.

4.2.11.1. Ethyl 4-(6-(4-(hexyloxy)phenyl)-2-hydroxyhexanamido)butanoate (24a): Yield 70%; white solid; mp 71–73 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.05 (d, 2H, arom, $J = 8.8$ Hz), 6.86 (t, 1H, NHCO , $J = 8.7$ Hz), 6.79 (d, 2H, arom, $J = 8.8$ Hz), 4.12 (q, 2H, OCH_2CH_3 , $J = 7.2$ Hz), 4.04–4.01 (m, 1H, CHOH), 3.91 (t, 2H, CH_2OPh , $J = 6.6$ Hz), 3.50 (br s, 1H, OH), 3.29 (q, 2H, NHCH_2 , $J = 6.6$ Hz), 2.54 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 2.33 (t, 2H, CH_2COOEt , $J = 7.4$ Hz), 1.89–1.51 (m, 8H, $4 \times \text{CH}_2$), 1.50–1.26 (m, 8H, $4 \times \text{CH}_2$), 1.25 (t, 3H, CH_3 , $J = 7.2$ Hz), 0.90 (t, 3H, CH_3 , $J = 6.6$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 174.3, 173.2, 157.1, 134.2, 129.1, 114.3, 71.9, 67.9, 60.5, 38.4, 34.8, 34.6, 31.6, 31.5, 31.3, 29.2, 25.6, 24.6, 24.5, 22.6, 14.1, 13.9. Anal. Calcd for $\text{C}_{24}\text{H}_{39}\text{NO}_5$: C, 68.38; H, 9.32; N, 3.32. Found: C, 68.26; H, 9.41; N, 3.25.

4.2.11.2. Ethyl 4-(2-hydroxy-5-(4-octylphenoxy)pentanamido)butanoate (24b): Yield 81%; white solid; mp 78–80 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.07 (d, 2H, arom, $J = 8.6$ Hz), 6.98 (t, 1H, NHCO , $J = 5.8$ Hz), 6.80 (d, 2H, arom, $J = 8.6$ Hz), 4.18–4.06 (m, 3H, CHOH , OCH_2CH_3), 3.96 (t, 2H, PhOCH_2 , $J = 6.0$ Hz), 3.52 (bs, 1H, OH), 3.30 (q, 2H, CONHCH_2 , $J = 7.0$ Hz), 2.52 (t, 2H, CH_2Ph , $J = 7.4$ Hz), 2.34 (t, 2H, CH_2COOEt , $J = 7.4$ Hz), 2.18–1.72 (m, 6H, $3 \times \text{CH}_2$), 1.65–1.47 (m, 2H, CH_2), 1.38–1.17 (m, 13H, $5 \times \text{CH}_2$, CH_3), 0.87 (t, 3H, CH_3); ^{13}C NMR (50 MHz, CDCl_3): δ 174.0, 173.2, 156.4, 135.4, 129.2, 114.2, 71.7, 67.9, 60.5, 38.4, 34.9, 31.8, 31.6, 31.5, 29.4, 29.2, 25.1, 24.7, 22.6, 14.1, 14.0. Anal. Calcd for $\text{C}_{25}\text{H}_{41}\text{NO}_5$: C, 68.93; H, 9.49; N, 3.22. Found: C, 68.85; H, 9.56; N, 3.15.

4.2.11.3. Ethyl 4-(2-hydroxy-12-(4-methylphenylsulfonamido)dodecanamido)butanoate (24c): Yield 59%; white solid; mp 57–59 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.69 (d, 2H, arom, $J = 8.0$ Hz), 7.25 (d, 2H, arom, $J = 8.6$ Hz), 6.74 (m, 1H, NHCO), 4.70 (m, 1H, SO_2NH), 4.13–4.03 (m, 3H, CHOH , CH_2CH_3), 3.42 (bs, 1H, OH), 3.27 (q, 2H, CONHCH_2 , $J = 7.0$ Hz), 2.90–2.78 (m, 2H, SO_2NHCH_2), 2.37 (s, 3H, CH_3Ph), 2.30 (t, 2H, CH_2COOEt , $J = 7.4$ Hz), 1.87–1.63 (m, 3H, CH_2 , CHH), 1.59–1.42 (m, 1H, CHH), 1.40–1.02 (m, 19H, $8 \times \text{CH}_2$, CH_3); ^{13}C NMR (50 MHz, CDCl_3): δ 174.2, 173.4, 143.2, 137.0, 129.6, 127.0, 72.0,

60.6, 43.2, 38.5, 34.8, 31.7, 29.4, 29.1, 28.8, 26.3, 24.8, 24.6, 21.5, 14.1. Anal. Calcd for $C_{25}H_{42}N_2O_6S$: C, 60.21; H, 8.49; N, 5.62. Found: C, 60.13; H, 8.57; N, 5.71.

4.2.11.4. Ethyl 5-(5-(4-(hexyloxy)phenoxy)-2-hydroxypentanamido)pentanoate

(24d): Yield 58%; white solid; mp 89–91 °C; 1H NMR (200 MHz, $CDCl_3$): δ 6.90–6.80 (m, 4H, arom), 6.75 (t, 1H, NH, J = 6.0 Hz), 4.30–4.10 (m, 1H, $CHOH$), 4.11 (q, 2H, OCH_2CH_3 , J = 6.0 Hz), 3.96 (t, 2H, OCH_2 , J = 6.0 Hz), 3.88 (t, 2H, OCH_2 , J = 6.0 Hz), 3.28 (q, 2H, $NHCH_2$, J = 6.0 Hz), 2.31 (t, 2H, CH_2COO , J = 6.0 Hz), 2.20–1.50 (m, 10H, $5 \times CH_2$), 1.50–1.30 (m, 6H, $3 \times CH_2$), 1.23 (t, 3H, CH_3 , J = 6.0 Hz), 0.89 (t, 3H, CH_3 , J = 6.0 Hz); ^{13}C NMR (50 MHz, $CDCl_3$): δ 173.5, 170.5, 153.7, 152.2, 115.5, 115.4, 71.9, 68.8, 68.6, 60.4, 38.6, 33.7, 32.2, 31.6, 29.3, 29.0, 25.7, 25.3, 22.6, 22.1, 14.2, 14.0. Anal. Calcd for $C_{24}H_{39}NO_6$: C, 65.88; H, 8.98; N, 3.20. Found: C, 65.62; H, 9.11; N, 3.32.

4.2.11.5. Ethyl 4-(2-hydroxy-13-phenyltridecanamido)butanoate (24e): Yield 87%; white

solid; mp 67–69 °C; 1H NMR (200 MHz, $CDCl_3$): δ 7.39–7.20 (m, 5H, Ph), 6.86 (t, 1H, $NHCO$, J = 5.8 Hz), 4.27–4.05 (m, 3H, $CHOH$, OCH_2CH_3), 3.40 (q, 2H, $NHCH_2$, J = 6.6 Hz), 3.22 (d, 1H, OH, J = 4.8 Hz), 2.68 (t, 2H, $PhCH_2$, J = 7.2 Hz), 2.43 (t, 2H, CH_2COOEt , J = 7.2 Hz), 2.00–1.81 (m, 4H, $NHCH_2CH_2$, CH_2CHOH), 1.78–1.58 (m, 4H, $2 \times CH_2$), 1.56–1.15 (m, 17H, $7 \times CH_2$, CH_3); ^{13}C NMR (50 MHz, $CDCl_3$): δ 174.2, 173.3, 142.9, 128.3, 128.1, 125.5, 72.1, 60.6, 38.4, 35.9, 34.9, 31.7, 31.5, 29.5, 29.4, 29.3, 29.2, 25.0, 24.6, 14.1. Anal. Calcd for $C_{25}H_{41}NO_4$: C, 71.56; H, 9.85; N, 3.34. Found: C, 71.44; H, 9.97; N, 3.26.

4.2.11.6. tert-Butyl 4-(5-(4-(hexyloxy)phenoxy)-2-hydroxypentanamido)butanoate

(30): Yield 72%; yellowish low mp solid; 1H NMR (200 MHz, $CDCl_3$): δ 7.01 (t, 1H, NH, J = 6.0 Hz), 6.90–6.60 (m, 4H, arom), 4.34 (br s, 1H, OH), 4.20–4.00 (m, 1H, $CHOH$), 3.89 (t, 2H, OCH_2 , J = 6.0 Hz), 3.84 (t, 2H, OCH_2 , J = 6.0 Hz), 3.25 (q, 2H, $NHCH_2$, J = 6.0 Hz), 2.22 (t, 2H, CH_2COO , J = 6.0 Hz), 2.10–1.60 (m, 8H, $4 \times CH_2$), 1.40 (s, 9H, $(C(CH_3)_3)$), 1.30–1.10 (m, 6H, $3 \times CH_2$), 0.86 (t, 3H, CH_3 , J = 6.0 Hz); ^{13}C NMR (50 MHz, $CDCl_3$): δ 174.1, 172.6, 153.3, 152.4, 115.3, 115.2, 80.5, 71.6, 68.5, 38.3, 32.7, 31.7, 31.5, 29.2, 27.9, 25.6, 25.1, 24.7, 22.5, 13.9. Anal. Calcd for $C_{25}H_{41}NO_6$: C, 66.49; H, 9.15; N, 3.10. Found: C, 66.28; H, 9.33; N, 3.24.

4.2.12 General method for the saponification—To a stirred solution of the 2-hydroxyamide ester **24a–d** (1.0 mmol) in a mixture of dioxane/ H_2O (9:1, 10 mL) 1 N NaOH (1.1 mL, 1.1 mmol) was added, and the mixture was stirred for 12 h at room temperature. The organic solvent was evaporated under reduced pressure, and H_2O (5 mL) was added. The aqueous layer was washed with EtOAc, acidified with 1 N HCl, and extracted with EtOAc (3×6 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and evaporated under reduced pressure. The residue was purified by column chromatography using $CHCl_3/MeOH$ 9:1 as eluent or recrystallized from $MeOH/Et_2O$.

4.2.12.1. 4-(6-(4-(Hexyloxy)phenyl)-2-hydroxyhexanamido)butanoic acid (26a): Yield 86%; white solid; 1H NMR (200 MHz, $CDCl_3$): δ 7.18–7.10 (m, 1H, $NHCO$), 7.05 (d, 2H, arom, J = 8.4 Hz), 6.80 (d, 2H, arom, J = 8.4 Hz), 4.18–4.05 (m, 1H, $CHOH$), 3.92 (t, 2H, CH_2OPh , J = 6.2 Hz), 3.47 (bs, 1H, OH), 3.42–3.17 (m, 2H, $CONHCH_2$), 2.54 (t, 2H,

PhCH₂, $J = 7.4$ Hz), 2.36 (t, 2H, CH₂COOH, $J = 6.6$ Hz), 1.85–1.20 (m, 16H, 8 × CH₂), 0.91 (t, 3H, CH₃, $J = 6.6$ Hz); ¹³C NMR (50 MHz, CDCl₃): δ 177.2, 175.4, 157.2, 134.3, 129.2, 114.3, 72.0, 68.0, 38.4, 34.8, 34.4, 31.6, 31.3, 29.3, 25.7, 24.7, 24.5, 22.6, 14.0. Anal. Calcd for C₂₂H₃₅NO₅: C, 67.15; H, 8.96; N, 3.56. Found: C, 67.01; H, 9.10; N, 3.47.

4.2.12.2. 4-(2-Hydroxy-5-(4-octylphenoxy)pentanamido)butanoic acid (26b): Yield 97%; white solid; mp 111–113 °C; ¹H NMR (200 MHz, CDCl₃): δ 7.21–7.12 (m, 1H, NHCO), 7.08 (d, 2H, arom, $J = 8.4$ Hz), 6.84 (d, 2H, arom, $J = 8.4$ Hz), 4.11 (dd, 1H, CHOH, $J_1 = 3.4$ Hz, $J_2 = 7.4$ Hz), 4.00 (t, 2H, PhOCH₂, $J = 5.8$ Hz), 3.56 (bs, 1H, OH), 3.32 (m, 2H, NHCH₂, $J = 7.0$ Hz), 2.56 (t, 2H, CH₂Ph, $J = 7.4$ Hz), 2.37 (t, 2H, CH₂COOH, $J = 7.4$ Hz), 2.02–1.75 (m, 6H, 3 × CH₂), 1.65–1.45 (m, 2H, CH₂), 1.42–1.21 (m, 10H, 5 × CH₂), 0.93 (t, 3H, CH₃, $J = 6.2$ Hz); ¹³C NMR (50 MHz, CDCl₃): δ 177.2, 176.9, 158.5, 136.0, 130.2, 115.4, 72.6, 68.8, 39.3, 36.0, 33.0, 32.9, 32.4, 32.2, 30.6, 30.4, 30.3, 26.2, 25.9, 23.7, 14.4. Anal. Calcd for C₂₃H₃₇NO₅: C, 67.78; H, 9.15; N, 3.44. Found: C, 67.65; H, 9.26; N, 3.36.

4.2.12.3. 4-(2-Hydroxy-12-(4-methylphenylsulfonamido)dodecanamido)butanoic acid (26c): Yield 92%; white solid; mp 58–60 °C; ¹H NMR (200 MHz, CDCl₃): δ 7.77 (d, 2H, arom, $J = 8.0$ Hz), 7.41 (d, 2H, arom, $J = 8.0$ Hz), 6.98 (bs, 1H, NHCO), 4.70 (bs, 1H, SO₂NH), 4.04 (dd, 1H, CHOH, $J_1 = 4.0$ Hz, $J_2 = 7.0$ Hz), 3.81 (bs, 1H, OH), 3.31 (t, 2H, CONHCH₂, $J = 7.0$ Hz), 2.86 (t, 2H, SO₂NHCH₂, $J = 7.0$ Hz), 2.47 (s, 3H, CH₃), 2.38 (t, 2H, CH₂COOH, $J = 7.4$ Hz), 1.92–1.74 (m, 4H, 2 × CH₂), 1.71–1.57 (m, 2H, SO₂NHCH₂CH₂), 1.45–1.15 (m, 14H, 7 × CH₂); ¹³C NMR (50 MHz, CDCl₃): δ 177.5, 176.9, 144.5, 139.0, 130.7, 128.0, 72.8, 44.0, 39.3, 35.7, 32.1, 30.5, 30.2, 27.6, 26.0, 25.9, 21.5. Anal. Calcd for C₂₃H₃₈N₂O₆S: C, 58.70; H, 8.14; N, 5.95. Found: C, 58.63; H, 8.27; N, 5.84.

4.2.12.4. 5-(5-(4-(Hexyloxy)phenoxy)-2-hydroxypentanamido)pentanoic acid (26d): Yield 100%; white solid; mp 68–70 °C; ¹H NMR (200 MHz, CDCl₃ + drops of CD₃OD): δ 7.03 (t, 1H, NH, $J = 6.0$ Hz), 6.90–6.60 (m, 4H, arom), 4.20–4.00 (m, 1H, CHOH), 3.92 (t, 2H, OCH₂, $J = 6.0$ Hz), 3.87 (t, 2H, OCH₂, $J = 6.0$ Hz), 3.25 (q, 2H, NHCH₂, $J = 6.0$ Hz), 2.31 (t, 2H, CH₂COOH, $J = 6.0$ Hz), 2.10–1.50 (m, 10H, 5 × CH₂), 1.50–1.10 (m, 6H, 3 × CH₂), 0.87 (t, 3H, CH₃, $J = 6.0$ Hz); ¹³C NMR (50 MHz, CDCl₃ + drops of CD₃OD): δ 176.5, 174.5, 153.4, 152.5, 115.4, 115.3, 71.6, 68.6, 38.4, 33.3, 33.0, 31.5, 29.3, 28.7, 25.7, 25.2, 22.6, 21.8, 14.0. Anal. Calcd for C₂₂H₃₅NO₆: C, 64.52; H, 8.61; N, 3.42. Found: C, 64.29; H, 8.83; N, 3.55.

4.2.13 General method for the oxidation of 2-hydroxyamides—To a solution of the 2-hydroxyamides **24a–c**, **26a–d** or **30** (1 mmol) in dry CH₂Cl₂ (10 mL) Dess-Martin periodinane (0.64 g, 1.5 mmol) was added and the mixture was stirred for 1 h at room temperature. The organic solvent was evaporated under reduce pressure and Et₂O (30 mL) was added. The organic phase was washed with saturated aqueous NaHCO₃ (20 mL) containing Na₂S₂O₃ (1.5 g, 9.5 mmol), H₂O (20 mL), dried over Na₂SO₄, and the organic solvent was evaporated under reduced pressure. The residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc as eluent. In the case of **26a–**

d, after reaction completion the organic solvent was evaporated and the residue was purified by column chromatography.

4.2.13.1. Ethyl 4-(6-(4-(hexyloxy)phenyl)-2-oxohexanamido)butanoate (25a): Yield 88%; white solid; mp 56–58 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.40–70.35 (m, 1H, NHCOCO), 7.29 (d, 2H, arom, $J = 8.4$ Hz), 7.03 (d, 2H, arom, $J = 8.4$ Hz), 4.36 (q, 2H, OCH_2CH_3 , $J = 7.4$ Hz), 4.14 (t, 2H, CH_2OPh , $J = 6.6$ Hz), 3.57 (q, 2H, NHCH_2 , $J = 7.0$ Hz), 3.16 (t, 2H, CH_2 , $J = 6.6$ Hz), 2.79 (t, 2H, PhCH_2 , $J = 8.0$ Hz), 2.59 (t, 2H, CH_2COOEt , $J = 7.4$ Hz), 2.18–1.19 (m, 4H, $2 \times \text{CH}_2$), 1.87–1.74 (m, 4H, $2 \times \text{CH}_2$), 1.70–1.53 (m, 6H, $3 \times \text{CH}_2$), 1.48 (t, 3H, CH_3 , $J = 7.4$ Hz), 1.13 (t, 3H, CH_3 , $J = 6.2$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 198.9, 172.9, 160.2, 157.2, 133.8, 129.1, 114.3, 67.9, 60.5, 38.6, 36.5, 34.6, 31.5, 30.9, 29.2, 25.7, 24.3, 22.6, 22.5, 14.1, 14.0. Anal. Calcd for $\text{C}_{24}\text{H}_{37}\text{NO}_5$: C, 68.71; H, 8.89; N, 3.34. Found: C, 68.64; H, 8.97; N, 3.45.

4.2.13.2. Ethyl 4-(5-(4-octylphenoxy)-2-oxopentanamido)butanoate (25b): Yield 60%; white solid; mp 49–51 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.22–7.15 (br s 1H, NHCOCO), 7.06 (d, 2H, arom, $J = 8.8$ Hz), 6.77 (d, 2H, arom, $J = 8.4$ Hz), 4.14 (q, 2H, OCH_2CH_3 , $J = 7.4$ Hz), 3.97 (t, 2H, CH_2OPh , $J = 6.2$ Hz), 3.34 (q, 2H, NHCH_2 , $J = 6.6$ Hz), 3.12 (t, 2H, CH_2COCO , $J = 7.0$ Hz), 2.53 (t, 2H, CH_2Ph , $J = 7.4$ Hz), 2.36 (t, 2H, CH_2COOEt , $J = 7.2$ Hz), 2.15–2.05 (m, 2H, CH_2), 1.98–1.79 (m, 2H, CH_2), 1.65–1.48 (m, 2H, CH_2), 1.29–1.15 (m, 13H, $5 \times \text{CH}_2$, CH_3), 0.88 (t, 3H, CH_3 , $J = 6.2$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 198.5, 172.9, 160.2, 156.6, 135.1, 129.1, 114.2, 66.5, 60.5, 38.7, 35.0, 33.5, 31.8, 31.7, 31.5, 29.4, 29.2, 24.3, 23.3, 22.6, 14.1, 14.0. Anal. Calcd for $\text{C}_{25}\text{H}_{39}\text{NO}_5$: C, 69.25; H, 9.07; N, 3.23. Found: C, 69.11; H, 9.20; N, 3.17.

4.2.13.3. Ethyl 4-(12-(4-methylphenylsulfonamido)-2-oxododecanamido)butanoate (25c): Yield 73%; white solid; mp 105–107 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.74 (d, 2H, arom, $J = 8.0$ Hz), 7.29 (d, 2H, arom, $J = 8.4$ Hz), 7.21–7.12 (m, 1H, COCONH), 4.74 (t, 1H, SO_2NH , $J = 5.8$ Hz), 4.12 (q, 2H, CH_2CH_3 , $J = 6.6$ Hz), 3.34 (q, 2H, CONHCH_2 , $J = 6.6$ Hz), 2.95–2.82 (m, 4H, SO_2NHCH_2 , CH_2COCO), 2.41 (s, 3H, CH_3Ph), 2.34 (t, 2H, CH_2 , $J = 7.2$ Hz), 1.94–1.80 (m, 2H, CH_2), 1.62–1.50 (m, 2H, CH_2), 1.50–1.35 (m, 2H, CH_2), 1.35–1.10 (m, 15H, $6 \times \text{CH}_2$, CH_3); ^{13}C NMR (50 MHz, CDCl_3): δ 199.2, 172.9, 160.3, 143.2, 137.0, 129.6, 127.0, 60.5, 43.1, 38.6, 36.6, 31.5, 29.4, 29.2, 29.1, 28.9, 26.4, 24.3, 23.0, 21.4, 14.1. Anal. Calcd for $\text{C}_{25}\text{H}_{40}\text{N}_2\text{O}_6\text{S}$: C, 60.46; H, 8.12; N, 5.64. Found: C, 60.32; H, 8.26; N, 5.52.

4.2.13.4. 4-(6-(4-(Hexyloxy)phenyl)-2-oxohexanamido)butanoic acid (27a): Yield 44%; white solid; mp 73–75 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.21–7.14 (m, 1H, NHCOCO), 7.07 (d, 2H, arom, $J = 8.4$ Hz), 6.81 (d, 2H, arom, $J = 8.4$ Hz), 3.93 (t, 2H, CH_2OPh , $J = 6.6$ Hz), 3.38 (q, 2H, CONHCH_2 , $J = 6.6$ Hz), 2.94 (t, 2H, CH_2COCO , $J = 6.6$ Hz), 2.57 (t, 2H, PhCH_2 , $J = 6.6$ Hz), 2.42 (t, 2H, CH_2COOH , $J = 7.4$ Hz), 1.94–1.83 (m, 2H, CH_2), 1.80–1.70 (m, 2H, CH_2), 1.63–1.43 (m, 4H, $2 \times \text{CH}_2$), 1.43–1.10 (m, 6H, $3 \times \text{CH}_2$), 0.91 (t, 3H, CH_3 , $J = 6.2$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 198.9, 178.0, 160.4, 157.3, 133.9, 129.2, 114.4, 68.0, 38.6, 36.6, 34.6, 31.6, 31.1, 31.0, 29.3, 25.7, 24.2, 22.7, 22.6, 14.0. Anal. Calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_5$: C, 67.49; H, 8.50; N, 3.58. Found: C, 67.35; H, 8.62; N, 3.44.

4.2.13.5. 4-(5-(4-Octylphenoxy)-2-oxopentanamido)butanoic acid (27b): Yield 60%; white solid; mp 49–51 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.32–7.20 (m, 1H, NHCOCO), 7.16 (d, 2H, arom, $J = 8.4$ Hz), 6.87 (d, 2H, arom, $J = 8.4$ Hz), 4.07 (t, 2H, PhOCH_2 , $J = 7.5$ Hz), 3.47 (q, 2H, NHCH_2 , $J = 6.6$ Hz), 3.22 (t, 2H, CH_2COCO , $J = 7.0$ Hz), 2.62 (t, 2H, PhCH_2 , $J = 7.4$ Hz), 2.51 (t, 2H, CH_2COOH , $J = 7.0$ Hz), 2.25–2.08 (m, 2H, CH_2), 2.08–1.90 (m, 2H, CH_2), 1.75–1.58 (m, 2H, CH_2), 1.45–1.23 (m, 10H, $5 \times \text{CH}_2$), 0.98 (t, 3H, CH_3 , $J = 7.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 198.5, 178.1, 160.3, 156.6, 135.3, 129.2, 114.2, 66.6, 38.6, 35.0, 33.6, 31.9, 31.7, 31.2, 29.5, 29.3, 24.2, 23.4, 22.6, 14.1. Anal. Calcd for $\text{C}_{23}\text{H}_{35}\text{NO}_5$: C, 68.12; H, 8.70; N, 3.45. Found: C, 68.03; H, 8.85; N, 3.27.

4.2.13.6. 4-(12-(4-Methylphenylsulfonamido)-2-oxododecanamido)butanoic acid (27c): Yield 55%; white solid; mp 98–100 °C; ^1H NMR (200 MHz, CD_3OD): δ 7.46 (d, 2H, arom, $J = 8.2$ Hz), 7.11 (d, 2H, arom, $J = 8.2$ Hz), 3.12–2.95 (m, 2H, CONHCH_2), 2.61–2.52 (m, 4H, SO_2NHCH_2 , CH_2COCO), 2.16 (s, 3H, CH_3), 2.07 (t, 2H, CH_2COOH , $J = 7.2$ Hz), 1.60–1.43 (m, 2H, $\text{CH}_2\text{CH}_2\text{COOH}$), 1.38–1.22 (m, 2H, $\text{SO}_2\text{NHCH}_2\text{CH}_2$), 1.20–0.80 (m, 14H, $7 \times \text{CH}_2$); ^{13}C NMR (50 MHz, acetone-d_6): δ 199.4, 174.0, 161.4, 143.2, 137.0, 130.0, 127.4, 43.5, 38.7, 36.9, 31.1, 30.6, 30.2, 29.8, 29.7, 29.5, 28.3, 26.8, 24.9, 23.5, 21.0. Anal. Calcd for $\text{C}_{23}\text{H}_{36}\text{N}_2\text{O}_6\text{S}$: C, 58.95; H, 7.74; N, 5.98. Found: C, 58.87; H, 7.82; N, 5.87.

4.2.13.7. 5-(5-(4-(Hexyloxy)phenoxy)-2-oxopentanamido)pentanoic acid (27d): Yield 76%; white solid; mp 91–93 °C; ^1H NMR (200 MHz, DMSO): δ 8.61 (t, 1H, NH, $J = 6.0$ Hz), 7.00–6.60 (m, 4H, arom), 3.88 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.86 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.09 (q, 2H, NHCH_2 , $J = 6.0$ Hz), 2.94 (t, 2H, CH_2COCO , $J = 6.0$ Hz), 2.20 (t, 2H, CH_2COOH , $J = 6.0$ Hz), 1.92 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.65 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.50–1.40 (m, 4H, $2 \times \text{CH}_2$), 1.40–1.20 (m, 6H, $3 \times \text{CH}_2$), 0.86 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, DMSO): δ 198.9, 176.5, 161.2, 152.8, 152.4, 115.4, 67.9, 67.1, 40.6, 33.7, 33.4, 31.1, 28.9, 28.3, 25.3, 23.1, 22.2, 22.0, 14.1. Anal. Calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_6$: C, 64.84; H, 8.16; N, 3.44. Found: C, 64.56; H, 8.35; N, 3.51.

4.2.13.8. *tert*-Butyl 4-(5-(4-(hexyloxy)phenoxy)-2-oxopentanamido)butanoate (31): Yield 84%; yellowish solid; mp 55–57 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.20 (t, 1H, NH, $J = 6.0$ Hz), 7.00–6.60 (m, 4H, arom), 3.89 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.84 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.28 (q, 2H, NHCH_2 , $J = 6.0$ Hz), 3.07 (t, 2H, CH_2COCO , $J = 6.0$ Hz), 2.23 (t, 2H, CH_2COO , $J = 6.0$ Hz), 2.03 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.88 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.79 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.70–1.60 (m, 2H, CH_2), 1.40 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.30–1.10 (m, 4H, $2 \times \text{CH}_2$), 0.86 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 198.4, 172.1, 160.1, 153.2, 152.5, 115.2, 80.4, 68.4, 67.0, 38.6, 33.5, 32.6, 31.4, 29.2, 27.9, 25.6, 24.3, 23.3, 22.5, 13.9. Anal. Calcd for $\text{C}_{25}\text{H}_{39}\text{NO}_6$: C, 66.79; H, 8.74; N, 3.12. Found: C, 66.60; H, 8.86; N, 3.22.

4.2.14. 14-(4-Ethoxy-4-oxobutylamino)-13,14-dioxotetradecanoic acid (28)—To a solution of **24e** (1.0 mmol) in a mixture of $\text{CCl}_4/\text{MeCN}/\text{H}_2\text{O}$ (1:1:2, 30 ml), NaIO_4 (6.2 g, 29.0 mmol) and $\text{RuCl}_3 \cdot 6\text{H}_2\text{O}$ (12 mg, 0.045 mmol) were added and the mixture was stirred overnight at room temperature. Dichloromethane (30 ml) was added and, after stirring for 10 min, the organic layer was separated, dried over Na_2SO_4 and concentrated under reduced

pressure. The residue was purified by column chromatography using petroleum ether (bp 40–60 °C)/EtOAc 1:1 as eluent. Yield 25%; white solid; mp 77–79 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.18–7.08 (m, 1H, NHCOCO), 4.20–4.09 (q, 2H, $\text{OHCCH}_2\text{CH}_3$, $J = 6.8$ Hz), 3.35 (q, 2H, NHCH_2 , $J = 6.8$ Hz), 2.91 (t, 2H, CH_2COCO , $J = 7.2$ Hz), 2.39–2.31 (m, 4H, CH_2COOEt , CH_2COOH), 2.00–1.80 (m, 2H, NHCH_2CH_2), 1.75–1.50 (m, 4H, $2 \times \text{CH}_2$), 1.40–1.10 (m, 17H, $7 \times \text{CH}_2$, CH_3); ^{13}C NMR (50 MHz, CDCl_3): δ 199.2, 179.1, 173.0, 160.3, 60.6, 38.7, 36.7, 33.9, 31.6, 29.7, 29.4, 29.3, 29.2, 29.1, 29.0, 24.6, 24.4, 23.1, 14.2. Anal. Calcd for $\text{C}_{20}\text{H}_{35}\text{NO}_6$: C, 62.31; H, 9.15; N, 3.63. Found: C, 62.25; H, 9.23; N, 3.57.

4.2.15. 4-(5-(4-(Hexyloxy)phenoxy)-2-oxopentanamido)butanoic acid (32)—A solution of the *tert*-butyl ester derivative **31** (450 mg, 1 mmol) in 50% TFA/ CH_2Cl_2 (2 mL) was stirred for 1 h at room temperature. The organic solvent was evaporated under reduced pressure and the residue was purified by recrystallization [EtOAc/petroleum ether (bp 40–60 °C)]. Yield 76%; white solid; mp 109–111 °C; ^1H NMR (200 MHz, CDCl_3): δ 7.16 (t, 1H, NH, $J = 6.0$ Hz), 7.00–6.60 (m, 4H, arom), 3.93 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.88 (t, 2H, OCH_2 , $J = 6.0$ Hz), 3.36 (q, 2H, NHCH_2 , $J = 6.0$ Hz), 3.10 (t, 2H, CH_2COCO , $J = 6.0$ Hz), 2.40 (t, 2H, CH_2COOH , $J = 6.0$ Hz), 2.08 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.88 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.73 (quintet, 2H, CH_2 , $J = 6.0$ Hz), 1.50–1.00 (m, 6H, $3 \times \text{CH}_2$), 0.89 (t, 3H, CH_3 , $J = 6.0$ Hz); ^{13}C NMR (50 MHz, CDCl_3): δ 198.5, 178.0, 160.3, 153.4, 152.6, 115.4, 68.6, 67.2, 38.6, 33.6, 31.6, 31.1, 29.3, 25.7, 24.2, 23.4, 22.6, 14.0. Anal. Calcd for $\text{C}_{21}\text{H}_{31}\text{NO}_6$: C, 64.10; H, 7.94; N, 3.56. Found: C, 63.91; H, 8.10; N, 3.70.

4.3. In vitro PLA₂ assays

All synthesized inhibitors were tested for inhibition of human GIVA cPLA₂, GVIA iPLA₂ and GV sPLA₂ using previously described mixed micelle-based assays.^{24–26} The buffer and substrate conditions were optimized for each enzyme assay as follows: (i) GIVA cPLA₂ substrate mixed-micelles were composed of 400 μM Triton X-100, 97 μM PAPC, 1.8 μM ^{14}C -labeled PAPC, and 3 μM PIP₂ in 100 mM HEPES buffer, pH 7.5, with 90 μM CaCl_2 , 2 mM DTT, and 0.1 mg/ml BSA; (ii) GVIA iPLA₂ substrate mixed-micelles were composed of 400 μM Triton X-100, 98.3 μM PAPC, and 1.7 μM ^{14}C -labeled PAPC in buffer containing 100 mM HEPES, pH 7.5, 2 mM ATP, and 4 mM DTT; (iii) GV sPLA₂ substrate mixed-micelles were composed of 400 μM Triton X-100, 98.3 μM PAPC, and 1.7 μM ^{14}C -labeled PAPC in buffer containing 50 mM Tris, pH 8.0, and 5 mM CaCl_2 .

Initial screening of compounds at 0.091 mole fraction inhibitor in mixed-micelles was carried out. Compounds displaying 25% or less inhibition of the assays were considered to have no inhibitory affect (designated N.D.). We report average percent inhibition for compounds displaying less than 85% enzyme inhibition. If the percent inhibition was greater than 85%, we determined its $X_{\text{I}}(50)$ by plotting percent inhibition versus inhibitor mole fraction. Inhibition curves were modeled in Graphpad Prism 5.0 using nonlinear regression targeted at symmetrical sigmoidal curves based on plots of % inhibition versus $\log(\text{inhibitor concentration})$, to calculate the reported $X_{\text{I}}(50)$ and associated error values.

Acknowledgments

This research has been co-financed by the European Union (European Regional Development Fund-ERDF) and Greek national funds through the Operational Program “Competitiveness and Entrepreneurship” of the National Strategic Reference Framework (NSRF) - Research Funding Program: “Phospholipases A₂ inhibitors: Developing a drug pipeline for the treatment of inflammatory neurological disorders” (G.K.) and in part by NIH grant RO1 20,501-40 (E.A.D.).

References

1. Leslie CC. J Lipid Res. 2015; 56:1386. [PubMed: 25838312]
2. Dennis EA, Cao J, Hsu Y-H, Magrioti V, Kokotos G. Chem Rev. 2011; 111:6130. [PubMed: 21910409]
3. Magrioti V, Kokotos G. Expert Opin Ther Pat. 2010; 20:1. [PubMed: 20021282]
4. Magrioti V, Kokotos G. Expert Opin Ther Pat. 2013; 23:1123. [PubMed: 23641951]
5. Street IP, Lin HK, Laliberte F, Ghomashchi F, Wang Z, Perrier H, Tremblay NM, Huang Z, Weech PK, Gelb MH. Biochemistry. 1993; 32:5935. [PubMed: 8018213]
6. McKew JC, Lovering F, Clark JD, Bemis J, Xiang Y, Shen M, Zhang W, Alvarez JC, Joseph-McCarthy D. Bioorg Med Chem Lett. 2003; 13:4501. [PubMed: 14643356]
7. McKew JC, Foley MA, Thakker P, Behnke ML, Lovering FE, Sum FW, Tam S, Wu K, Shen MWH, Zhang W, Gonzalez M, Liu S, Mahadevan A, Sard H, Khor SP, Clark JD. J Med Chem. 2006; 49:135. [PubMed: 16392799]
8. Lee KL, Foley MA, Chen L, Behnke ML, Lovering FE, Kirincich SJ, Wang W, Shim J, Tam S, Shen MWH, Khor S, Xu X, Goodwin DG, Ramarao MK, Nickerson-Nutter C, Donahue F, Ku MS, Clark JD, McKew JC. J Med Chem. 2007; 50:1380. [PubMed: 17305324]
9. McKew JC, Lee KL, Shen MWH, Thakker P, Foley MA, Behnke ML, Hu B, Sum FW, Tam S, Hu Y, Chen L, Kirincich SJ, Michalak R, Thomason J, Ipek M, Wu K, Wooder L, Ramarao MK, Murphy EA, Goodwin DG, Albert L, Xu X, Donahue F, Ku MS, Keith J, Nickerson-Nutter CL, Abraham WM, Williams C, Hegen M, Clark JD. J Med Chem. 2008; 51:3388. [PubMed: 18498150]
10. Lee KL, Behnke ML, Foley MA, Chen L, Wang W, Vargas R, Nunez J, Tam S, Mollova N, Xu X, Shen MWH, Ramarao MK, Goodwin DG, Nickerson-Nutter CL, Abraham WM, Williams C, Clark JD, McKew JC. Bioorg Med Chem. 2008; 16:1345. [PubMed: 17998165]
11. Seno K, Okuno T, Nishi K, Murakami Y, Yamada K, Nakamoto S, Ono T. Bioorg Med Chem Lett. 2001; 11:587. [PubMed: 11229777]
12. Ono T, Yamada K, Chikazawa Y, Ueno M, Nakamoto S, Okuno T, Seno K. Biochem J. 2002; 363:727. [PubMed: 11964173]
13. Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T, Wada M, Fujii Y, Yamada M, Ogawa T, Okada T, Hashizume H, Kii M, Hara S, Hagishita S, Nakamoto S, Yamada K, Chikazawa Y, Ueno M, Teshirogi I, Ono T, Ohtani M. J Med Chem. 2000; 43:1041. [PubMed: 10737736]
14. Tai N, Kuwabara K, Kobayashi M, Yamada K, Ono T, Seno K, Gahara Y, Ishizaki J, Hori Y. Inflammation Res. 2010; 59:53.
15. Connolly S, Bennion C, Botterell S, Croshaw PJ, Hallam C, Hardy K, Hartopp P, Jackson CG, King SJ, Lawrence L, Mete A, Murray D, Robinson DH, Smith GM, Stein L, Walters I, Wells E, Withnall WJ. J Med Chem. 2002; 45:1348. [PubMed: 11882004]
16. Walters I, Bennion C, Connolly S, Croshaw PJ, Hardy K, Hartopp P, Jackson CG, King SJ, Lawrence L, Mete A, Murray D, Robinson DH, Stein L, Wells E, John Withnall W. Bioorg Med Chem Lett. 2004; 14:3645. [PubMed: 15203135]
17. Ludwig J, Bovens S, Brauch C, Elfringhoff AS, Lehr M. J Med Chem. 2006; 49:2611. [PubMed: 16610804]
18. Hess M, Schulze Elfringhoff A, Lehr M. Bioorg Med Chem. 2007; 15:2883. [PubMed: 17320401]
19. Fritsche A, Elfringhoff AS, Fabian J, Lehr M. Bioorg Med Chem. 2008; 16:3489. [PubMed: 18321717]
20. Bovens S, Kaptur M, Elfringhoff AS, Lehr M. Bioorg Med Chem Letters. 2009; 19:2107.

21. Forster L, Ludwig J, Kaptur M, Bovens S, Elfringhoff AS, Holtfrerich A, Lehr M. *Bioorg Med Chem.* 2010; 18:945. [PubMed: 20005725]
22. Drews A, Bovens S, Roebrock K, Sunderkotter C, Reinhardt D, Schafers M, Van Der Velde A, Schulze Elfringhoff A, Fabian J, Lehr M. *J Med Chem.* 2010; 53:5165. [PubMed: 20583844]
23. Kokotos G, Kotsovolou S, Six DA, Constantinou-Kokotou V, Beltzner CC, Dennis EA. *J Med Chem.* 2002; 45:2891. [PubMed: 12086476]
24. Kokotos G, Six DA, Loukas V, Smith T, Constantinou-Kokotou V, Hadjipavlou-Litina D, Kotsovolou S, Chiou A, Beltzner CC, Dennis EA. *J Med Chem.* 2004; 47:3615. [PubMed: 15214789]
25. Stephens D, Barbayianni E, Constantinou-Kokotou V, Peristeraki A, Six DA, Cooper J, Harkewicz R, Deems RA, Dennis EA, Kokotos G. *J Med Chem.* 2006; 49:2821. [PubMed: 16640343]
26. Six DA, Barbayianni E, Loukas V, Constantinou-Kokotou V, Hadjipavlou-Litina D, Stephens D, Wong AC, Magrioti V, Moutevelis-Minakakis P, Baker SF, Dennis EA, Kokotos G. *J Med Chem.* 2007; 50:4222. [PubMed: 17672443]
27. Barbayianni E, Stephens D, Grkovich A, Magrioti V, Hsu YH, Dolatzas P, Kalogiannidis D, Dennis EA, Kokotos G. *Bioorg Med Chem.* 2009; 17:4833. [PubMed: 19443224]
28. Yaksh TL, Kokotos G, Svensson CI, Stephens D, Kokotos CG, Fitzsimmons B, Hadjipavlou-Litina D, Hua XY, Dennis EA. *J Pharmacol Exp Therap.* 2006; 316:466. [PubMed: 16203828]
29. Walters I, Bennion C, Connolly S, Croshaw PJ, Hardy K, Hartopp P, Jackson CG, King SJ, Lawrence L, Mete A, Murray D, Robinson DH, Stein L, Wells E, Withnall WJ. *Bioorg Med Chem Lett.* 2004; 14:3645. [PubMed: 15203135]
30. Chen L, Wang W, Lee KL, Shen MW, Murphy EA, Zhang W, Xu X, Tam S, Nickerson-Nutter C, Goodwin DG, Clark JD, McKew JC. *J Med Chem.* 2009; 52:1156. [PubMed: 19178292]
31. Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC. *Bioorg Med Chem.* 2009; 17:4383. [PubMed: 19482480]
32. Mouchlis VD, Bucher D, McCammon JA, Dennis EA. *PNAS.* 2015; 112:E516. [PubMed: 25624474]
33. Mouchlis VD, Dennis EA. *Adv Biol Regul.* 2016; 61:17. [PubMed: 26774606]
34. Lipinski C, Lombardo F, Dominy B, Feeney P. *Adv Drug Deliv Rev.* 1997; 23:3.
35. Baskakis C, Magrioti V, Cotton N, Stephens D, Constantinou-Kokotou V, Dennis EA, Kokotos G. *J Med Chem.* 2008; 51:8027. [PubMed: 19053783]
36. Kokotos G, Hsu YH, Burke JE, Baskakis C, Kokotos CG, Magrioti V, Dennis EA. *J Med Chem.* 2010; 53:3602. [PubMed: 20369880]
37. Kokotos G. *Synthesis.* 1990:299.
38. Nunez MT, Martin VS. *J Org Chem.* 1990; 55:1928.
39. Moutevelis-Minakakis P, Sinanoglou C, Loukas V, Kokotos G. *Synthesis.* 2005:933.
40. Barbayianni E, Antonopoulou G, Kokotos G. *Pure Appl Chem.* 2012; 84:1877.

Figure 1.
ClogP values for GIVA cPLA₂ inhibitors.

Figure 2.
Replacements of the long aliphatic chain of 2-oxoamides designed in this work.

Scheme 1.

Reagents and conditions: (a) $\text{Br}^-\text{P}^+\text{Ph}_3(\text{CH}_2)_9\text{COOCH}_3$, NaH, THF, reflux; (b) H_2 , 10% Pd/C, EtOH; (c) K_2CO_3 , ethyl 4-bromobutyrate, acetone, reflux; (d) DIBALH, Et_2O or LiAlH_4 , THF, reflux; (e) TsCl, NMM, THF; (f) i. NMM, ClCO_2Et , THF; ii. NaBH_4 , MeOH.

Scheme 2.

Reagents and conditions: (a) NaOCl, TEMPO, NaBr, NaHCO₃, EtOAc/PhCH₃/H₂O 3:3:0.5, −5 °C; (b) i. NaHSO₃, CH₂Cl₂, H₂O; ii. KCN, H₂O; (c) cone. HCl; (d) KOH, EtOH/H₂O.

Scheme 3.

Reagents and conditions: (a) **21a-e**, Et₃N, WSCI, HOBT, CH₂Cl₂; (b) Dess-Martin periodinane, CH₂Cl₂; (c) NaOH 1N, dioxane/H₂O 9:1; (d) NaIO₄, RuCl₃.H₂O, CH₃CN/CCl₄/H₂O 1:1:2.

Scheme 4.

Reagents and conditions: (a) **21d**, Et_3N , WSCI, HOBT, CH_2Cl_2 ; (b) Dess-Martin periodinane, CH_2Cl_2 ; (c) 50% TFA/ CH_2Cl_2 .

Table 1

Inhibition of PLA₂ by 2-oxoamides^a

Number	Structure	ClogP ^b	GIVA cPLA ₂		GVIA hPLA ₂		GV sPLA ₂	
			% Inhibition	X _I (50)	% Inhibition	X _I (50)	% Inhibition	% Inhibition
AX048 ^{2,8}		7.61	0.022 ± 0.009		0.027 ± 0.009			
AX006 ^{2,8}		6.63	0.024 ± 0.015		N.D.			
25b		7.39	49.3 ± 2.0		94.7 ± 0.5	0.014 ± 0.003	40.6 ± 5.9	
25a		6.30	>85	0.020 ± 0.006	95.1 ± 0.6	0.013 ± 0.003	33.8 ± 6.0	
27b		6.41	>85	0.023 ± 0.005	N.D.		N.D.	
27a		5.32	>85	0.016 ± 0.004	N.D.		N.D.	
32		4.94	63.6 ± 2.6		81.1 ± 1.0		N.D.	
27d		4.82	88.0 ± 0.9	0.013 ± 0.002	82.5 ± 1.4		N.D.	
25c		5.69	59.3 ± 3.1		N.D.		N.D.	

Number	Structure	ClogP ^b	GIVA cPLA ₂		GVIA iPLA ₂		GV sPLA ₂	
			% Inhibition	X _I (50)	% Inhibition	X _I (50)	% Inhibition	
27c		4.71	N.D.		N.D.		N.D.	
28		4.61	N.D.		N.D.		N.D.	

^a Average percent inhibition and standard error (n = 3) are reported for each compound at 0.091 mol fraction. X_I(50) values were determined for inhibitors with greater than 85% inhibition. N.D. signifies compounds with less than 25% inhibition (or no detectable inhibition).

^b Calculated by ChemOffice Ultra 11.00.